The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Budesonide Market During 2026–2030?
The budesonide market size has experienced robust growth in recent years. This market is projected to expand from $10.26 billion in 2025 to $10.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. The growth observed in the past can be attributed to rising asthma and COPD prevalence, widespread adoption of corticosteroids, the expansion of inhalation therapies, increased IBD diagnosis, and improvements in drug delivery technologies.
The budesonide market size is anticipated to demonstrate significant expansion in the upcoming years. It is projected to reach $13.72 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. The projected increase during this period stems from factors such as an aging population, a rise in chronic inflammatory conditions, greater adoption of generic drugs, the expansion of home-based treatments, and an escalating burden of respiratory diseases. Key developments expected within the forecast period encompass the growing application of inhaled corticosteroids in managing chronic respiratory illnesses, increased integration into inflammatory bowel disease management, a rising preference for targeted localized steroid therapies, the proliferation of generic budesonide formulations, and enhanced utilization in long-term maintenance treatment.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp
What Drivers Are Expected To Influence The Budesonide Market During The Forecast Period?
A surge in the occurrence of respiratory ailments is anticipated to propel the expansion of the budesonide market moving forward. Respiratory diseases are medical conditions impacting the organs and tissues responsible for regulating gas exchange in air-breathing animals. The heightened prevalence of these illnesses stems from increasing air pollution, particularly exposure to particulate matter and allergens, which significantly influences the rates of asthma and chronic obstructive lung disease. Budesonide is utilized in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) to diminish inflammation, improve airflow, and prevent symptoms like wheezing and shortness of breath. For instance, in August 2025, according to the Centers for Disease Control and Prevention, a Switzerland-based public health agency, 90% of the nation’s 4.9 trillion dollars in annual health care spending is attributed to individuals with chronic and mental health conditions, with more than 84,000 Americans dying each year from heart disease or stroke and the costs associated with cardiovascular diseases projected to reach roughly 2 trillion dollars by 2050. Consequently, the rising prevalence of respiratory diseases will drive the growth of the budesonide market.
How Are The Various Segments Of The Budesonide Market Categorized?
The budesonide market covered in this report is segmented –
1) By Type: Inhalation Powder, Aerosols, Tablets And Capsules
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications
Subsegments:
1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)
2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers
3) By Tablets And Capsules: Oral Tablets, Oral Capsules
What Trends Are Affecting The Expansion Of The Budesonide Market?
Key companies within the budesonide market are concentrating on progress in respiratory treatment, including oral therapy, to improve patient convenience, encourage better treatment adherence, and broaden the range of therapeutic choices for managing asthma and various other respiratory conditions. Oral therapy budesonide refers to a budesonide preparation consumed by mouth, primarily utilized for treating inflammatory ailments. For example, in February 2024, Takeda Pharmaceuticals, a pharmaceutical company based in Japan, declared that the Food and Drug Administration (FDA), a federal agency located in the US, had sanctioned EOHILIA, a budesonide oral suspension, establishing it as the initial and sole FDA-approved oral medicine for patients aged 11 and above suffering from eosinophilic esophagitis (EoE). Furthermore, the FDA approved EOHILIA 2 mg twice daily, basing its decision on efficacy and safety data from two multicenter, randomized, double-blind, parallel-group, placebo-controlled investigations, each lasting 12 weeks, involving individuals aged 11 to 56 with EoE.
Which Major Firms Influence Developments In The Budesonide Market?
Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.
Read the full budesonide market report here:
https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report
Which Region Is Forecast To Lead The Budesonide Market In Terms Of Market Size?
North America was the largest region in the budesonide market in 2025. The regions covered in the budesonide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Budesonide Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21121&type=smp
Browse Through More Reports Similar to the Global Budesonide Market 2026, By The Business Research Company
Cannabis Capsule Market Report 2026
https://www.thebusinessresearchcompany.com/report/cannabis-capsule-global-market-report
Tea Capsule Market Report 2026
https://www.thebusinessresearchcompany.com/report/tea-capsule-global-market-report
Cannabis Extract Market Report 2026
https://www.thebusinessresearchcompany.com/report/cannabis-extract-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model